

Richard Haynes

From: Elaine Chick <elaine.chick@admin.ox.ac.uk>
Sent: 15 February 2021 13:11
To: Richard Haynes
Cc: oxfordjro@mail.studyline.uk.com
Subject: RE: RECOVERY SA16
Attachments: 281712_Substantial Amendment 16__A2.pdf; 281712_Substantial Amendment 16_.pdf

Dear Richard

I can confirm that the above referenced substantial amendment has been reviewed in CTRG and we are happy for it to be submitted to the relevant organisations for approval. This email can be forwarded as confirmation of sponsor approval for the amendment as required.

Please find attached the PDF version of the signed and locked amendment tool and annex 2.

In order to ensure validation of your submission by the relevant organisations, please submit both tracked and clean copies of all amended documents and copy in the CTRG generic email address (ctrq@admin.ox.ac.uk) so the Sponsor has final documents and is included in subsequent correspondence.

Please make your MHRA submission, through the MHRA submission platform.

Please send a copy of the approval letter to the CTRG generic email address (ctrq@admin.ox.ac.uk) once you have received them. Please do not implement your amendment until all approvals are in place.

Best wishes
Elaine

Elaine Chick

Deputy Head | Clinical Trials and Research Governance (CTRG)
Research Services, University of Oxford
Joint Research Office
Boundary Brook House, Churchill Drive Oxford OX3 7GB

Please note I usually work Monday-Thursday only

☎ 01865 616481
✉ elaine.chick@admin.ox.ac.uk
researchsupport.admin.ox.ac.uk



Guidance (FAQs) for Clinical Research during the COVID-19 national emergency can be found on: <https://researchsupport.admin.ox.ac.uk/ctrq>

PID14892-A017-SP001-AC001